跳至主要内容
临床试验/NCT03968549
NCT03968549Unknown不适用

Study of the Importance of Intestinal Microbiota in Patients With Heart Failure - Randomized, Double-blind Study

University of Sao Paulo General Hospital1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2018年11月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
58
试验地点
1
主要终点
Effects of probiotics in serum levels of TNF-alpha

研究概览

简要总结

Cachexia is a very common condition in patients with advanced heart failure (HF) and is considered a predictor of mortality. Studies have been carried out in an attempt to discover the mechanisms that leads to cachexia in order to improve the therapies and the survival of these patients. Some of these studies give the hypothesis that the gastrointestinal tract, more precisely the intestine, can collaborate with cachexia. Some of these studies suggest that, the intestinal mucosa, due to hypoperfusion, becomes more permeable to some substances, as like endotoxins, being the lipopolysaccharide (LPS) one of them. The circulating LPS can stimulate the increase of tumor necrosis alpha (TNF-alpha) further increasing the inflammation and, consequently, contributing to the worsening of prognosis. The intestinal microbiota is also affected by hypoperfusion, contributing with increase of permeability. As known, probiotics can help to maintain or recover the microbiota and maintain a healthy intestinal barrier. In view of the importance of microbiota to inflammation in the prognosis of the patients and the performance of microbiota in maintenance of intestinal barrier, this study has as primary objective to verify the influence of supplementation of the probiotic Lactobacillus acidophilus (LA) in the lowering of serum levels of TNF-alpha in the patients with HF.

详细描述

The present study will be a clinical trial compounded by two parallel arms, randomized, double-blind (researcher-patient), placebo-controlled, with patients with heart failure (HF), functional class according the New York Heart Association (NYHA) III and IV. It will be included 58 patients, 29 will receive probiotics and 29 will receive placebo. These patients will be accompanied during 6 months and should take one capsule every day during the study. In the beginning of the study and at the end, venous blood sample will be collected of each patient for laboratory measurement of TNF alpha, interleukins 1,6 and 10, LPS, B-type natriuretic peptide (BNP) and C-reactive protein (CRP). To establish the normality pattern of these markers studied, a control group, with healthy individuals, will be performed.An anthropometric evaluation will be performed with measurements of weigh, height, arm circumference, triceps skin fold. According to nutritional status, it will be calculated the caloric and protein needs of each patient and, to monitor the consumption, in each consult will be applied the 24-hour food recall and calculated the consumption from it. In order to measure the appetite of the patients, in each consult, an appetite questionnaire will be applied. To statistical analysis, the test of Kolmogorov-Smirnov will be used to assess whether the distribution is normal for the quantitative variables. If the variable follows normal distribution, it will be described as mean and standard deviation, otherwise, it will be described as median and interquartile range. The groups will be compared using t-Student or Mann-Whitney tests. The categorical variables will be presented descriptively with absolute and relative frequencies. The association between categorical variables will be analyzed with chi square test or Fisher exact test or likelihood ratio test. For the repeated measures, will be used the ANOVA test or Friedman test and Wilcoxon signs. The analyzes will be performed according to the intent-to-treat principle and the two-tailed tests. The value of p<0,5 will be considered statistically significant.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with heart failure NYHA functional class III and IV;
  • Medications optimized for at least 2 months;
  • No hospitalizations for HF decompensated or acute myocardial infarction in the last 30 days;
  • Have signed the Free and Informed Consent Form

排除标准

  • Do not accept to participate in the study or do not signed the Free and Informed Consent Form
  • Have used antibiotics and/or corticosteroids in the last 30 days;
  • Clinical conditions that can affect the inflammatory profile such as inflammatory bowel disease, arthrosis, among others;
  • Be pregnant;
  • Have been submitted to a cardiac surgery in the last 6 months or other surgery in the last 3 months

研究组 & 干预措施

Placebo

Placebo Comparator

These patients will receive capsules containing vegetable oil and corn starch

干预措施: Placebo (Other)

Probiotic

Active Comparator

These patients will receive capsules containing Lactobacillus acidophilus

干预措施: Probiotic (Dietary Supplement)

结局指标

主要结局

Effects of probiotics in serum levels of TNF-alpha

时间窗: six months

Probiotics should improve serum levels of tumor necrosis alpha (TNF-alpha)

次要结局

  • Effects of probiotics in serum level of interleukin 6 (IL 6) (pg/mL)(six months)
  • Effects of probiotics in serum levels of interleukin 1 (IL 1) (pg/mL)(six months)
  • Effects of probiotics in serum levels of lipopolysaccharide LPS (ng/mL)(six months)
  • Effects of probiotics in serum levels of interleukin 10 (IL 10)(pg/mL)(six months)
  • Effects of probiotics in serum levels of B-type natriuretic peptide (BNP) (pg/mL)(six months)
  • Effects of probiotics in serum levels of C-reactive protein (CRP) (mg/L)(six months)
  • Effects of probiotics in appetite(six months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fernando Bacal

Director of Heart Transplant Unit

University of Sao Paulo General Hospital

研究点 (1)

Loading locations...

相似试验